Efficacy and safety of finasteride (5 alpha-reductase inhibitor) monotherapy in patients with benign prostatic hyperplasia. a critical review of the literature
01 Pubblicazione su rivista
Busetto Gian Maria, Del Giudice Francesco, D'Agostino Daniele, Romagnoli Daniele, Minervini Andrea, Rocco Bernardo, Antonelli Alessandro, Celia Antonio, Schiavina Riccardo, Cindolo Luca, Chung Benjamin I, Kim Jae Heon, Maggi Martina, Sciarra Alessandro, De Berardinis Ettore, Porreca Angelo
ISSN: 1124-3562
Combination therapy with 5 alpha-reductase inhibitor (5-ARI) and alpha-blocker can be considered as a gold standard intervention for medical management of lower urinary tract symptoms related to benign prostatic hyperplasia (LUTS/BPH). On the other hand, 5-ARI monotherapy and in particular Finasteride alone is currently getting focus of attention especially due to lack of systematic reviews investigating efficacy outcomes and/or adverse events associated.